A multicenter, retrospective, observational study was conducted to explore effectiveness and
safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory …

Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an
important component of therapeutic decision-making. This multi-centric, retrospective …

Abstract Introduction Ixazomib (Ixa) represents the first orally available proteasome inhibitor
(PI) approved by FDA and EMA for the treatment of RRMM, based on results of the …

Objective: To evaluate the efficacy and safety profile of ixazomib/lenalidomide/
dexamethasone (IRd) in Chinese patients with relapsed/refractory multiple myeloma (MM) …

Ixazomib is approved for use in combination with lenalidomide and dexamethasone (IRd) for
patients with multiple myeloma (MM) who received at least one previous therapy …

Real-world studies permit inclusion of a more diverse patient population and provide more
information on the effectiveness of treatments used in routine clinical practice. This …

Objectives In the absence of head-to-head comparisons across relapsed/refractory multiple
myeloma (RRMM) treatments following the approval of the oral proteasome inhibitor …

Background/aim Ixazomib, lenalidomide, and dexamethasone (IRd) have proven efficacy
and an excellent safety profile in relapsed and/or refractory multiple myeloma (RRMM) …

Objectives This study aimed to investigate real‐world data of ixazomib plus lenalidomide
and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple …

Introduction Ixazomib, lenalidomide, and dexamethasone (IRd) have been approved for the
treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the …